RANCHO SANTA MARGARITA, Calif., Feb. 27, 2003 (PRIMEZONE) - BioCurex, Inc. (OTCBB:BOCX) announced that an interview featuring Dr. Gerald Wittenberg, the company's Chairman, is currently available on CEOcast (http://www.ceocast.com) (2/26/2002) in real audio.
In the interview, Dr. Wittenberg discusses BioCurex's technologies, products and their applications as well as the company's position and future plans.
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAFTM kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from their Website at http://www.biocurex.com.
CEOcast is the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies. Organized by industry, its analysts average over 15 years experience covering and evaluating Wall Street's leading companies.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.